How much funding has OncXerna Therapeutics raised?

OncXerna Therapeutics has raised $110.0M in total funding, most recently a Venture Round.

When was OncXerna Therapeutics founded?

OncXerna Therapeutics was founded in 2018.

Where is OncXerna Therapeutics headquartered?

OncXerna Therapeutics is headquartered in Waltham, Massachusetts, United States.

What industry is OncXerna Therapeutics in?

OncXerna Therapeutics operates in Biotech, Healthcare.

How many employees does OncXerna Therapeutics have?

OncXerna Therapeutics has 11-50 employees.

OncXerna Therapeutics

Biomarker-driven oncology therapeutics

Waltham, United States · Founded 2018 · $110.0M raised

Biotech

Healthcare

Headquarters: Waltham, Massachusetts
Employees: 11–50
Founded: 2018
Business Model: B2B

Website: oncxerna.com
Total Funding: $110.0M
Last Round: $30.0M Venture RoundMar 2022
Rounds: 2

About

OncXerna Therapeutics is a clinical-stage oncology biopharmaceutical company developing biomarker-driven antiangiogenic therapies to treat solid tumors. The company's lead program focuses on navicixizumab, a DLL4/VEGF bispecific antibody targeting tumor angiogenesis and Notch signaling pathways. OncXerna's proprietary Xerna TME Panel is a machine learning-based tumor microenvironment classifier used to identify patients likely to respond to antiangiogenic treatment, enabling precision oncology approaches. The company has conducted Phase 1b studies in platinum-resistant ovarian cancer and other solid tumor indications. OncXerna is headquartered in Waltham, Massachusetts, and has raised over $123 million in Series C financing. The company is focused on advancing biomarker-selected patient populations to improve clinical outcomes in oncology.

Summary

OncXerna Therapeutics is a Biotech company based in Waltham, United States, founded in 2018. It has raised $110.0M in total across 2 rounds, most recently a $30.0M Venture Round round in Mar 2022.